
    
      The Phase 2a portion of this study is completed. The following entries reflect the Phase 2a
      portion of this study only. The Phase 2b portion of the study was not enrolled. Based on
      emerging data regarding the corresponding low efficacy of cetuximab in patients with KRAS
      mutations, as well as revised NKTR-102 clinical development plans, the Phase 2b portionof the
      study was not completed.
    
  